Talimogene laherparepvec (Imlygic®)

Assessment Status Rapid Review Complete
Drug Talimogene laherparepvec
Brand Imlygic®
Indication For the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
Assessment Process
Rapid review commissioned 16/02/2016
Rapid review completed 14/03/2016
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.

Not considered cost-effective due to non-submission of full pharmacoeonomic assessment.